飛利信(300287.SZ):擬簽署10.85億元雲服務意向合作協議
格隆匯7月25日丨飛利信(300287.SZ)公佈,公司第六屆董事會第九次會議審議通過《關於簽訂日常經營重大合同的議案》,擬與某人工智能頭部企業(簡稱“甲方”)簽署《雲服務意向合作協議》,合同總金額為人民幣10.85億元(含税)。本協議簽訂後,甲方將向乙方擬採購算力技術服務,乙方提供的是人工智能訓練算力服務器、訓練網絡設備等對應的計算資源服務。服務期為乙方負責提供的服務通過甲方驗收後60個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.